tetano
Editor, Senior Moderator
Pathogens
. 2024 Jan 23;13(2):97.
doi: 10.3390/pathogens13020097. Multivalent Epigraph Hemagglutinin Vaccine Protects against Influenza B Virus in Mice
Erika Petro-Turnquist[SUP] 1 [/SUP], Brigette Corder Kampfe[SUP] 1 2 [/SUP], Amber Gadeken[SUP] 3 [/SUP], Matthew J Pekarek[SUP] 1 [/SUP], Eric A Weaver[SUP] 1 [/SUP]
Affiliations
Influenza B virus is a respiratory pathogen that contributes to seasonal epidemics, accounts for approximately 25% of global influenza infections, and can induce severe disease in young children. While vaccination is the most commonly used method of preventing influenza infections, current vaccines only induce strain-specific responses and have suboptimal efficacy when mismatched from circulating strains. Further, two influenza B virus lineages have been described, B/Yamagata-like and B/Victoria-like, and the limited cross-reactivity between the two lineages provides an additional barrier in developing a universal influenza B virus vaccine. Here, we report a novel multivalent vaccine using computationally designed Epigraph hemagglutinin proteins targeting both the B/Yamagata-like and B/Victoria-like lineages. When compared to the quadrivalent commercial vaccine, the Epigraph vaccine demonstrated increased breadth of neutralizing antibody and T cell responses. After lethal heterologous influenza B virus challenge, mice immunized with the Epigraph vaccine were completely protected against both weight loss and mortality. The superior cross-reactive immunity conferred by the Epigraph vaccine immunogens supports their continued investigation as a universal influenza B virus vaccine.
Keywords: epigraph; influenza B virus; vaccine; victoria lineage; yamagata lineage.
. 2024 Jan 23;13(2):97.
doi: 10.3390/pathogens13020097. Multivalent Epigraph Hemagglutinin Vaccine Protects against Influenza B Virus in Mice
Erika Petro-Turnquist[SUP] 1 [/SUP], Brigette Corder Kampfe[SUP] 1 2 [/SUP], Amber Gadeken[SUP] 3 [/SUP], Matthew J Pekarek[SUP] 1 [/SUP], Eric A Weaver[SUP] 1 [/SUP]
Affiliations
- PMID: 38392835
- DOI: 10.3390/pathogens13020097
Influenza B virus is a respiratory pathogen that contributes to seasonal epidemics, accounts for approximately 25% of global influenza infections, and can induce severe disease in young children. While vaccination is the most commonly used method of preventing influenza infections, current vaccines only induce strain-specific responses and have suboptimal efficacy when mismatched from circulating strains. Further, two influenza B virus lineages have been described, B/Yamagata-like and B/Victoria-like, and the limited cross-reactivity between the two lineages provides an additional barrier in developing a universal influenza B virus vaccine. Here, we report a novel multivalent vaccine using computationally designed Epigraph hemagglutinin proteins targeting both the B/Yamagata-like and B/Victoria-like lineages. When compared to the quadrivalent commercial vaccine, the Epigraph vaccine demonstrated increased breadth of neutralizing antibody and T cell responses. After lethal heterologous influenza B virus challenge, mice immunized with the Epigraph vaccine were completely protected against both weight loss and mortality. The superior cross-reactive immunity conferred by the Epigraph vaccine immunogens supports their continued investigation as a universal influenza B virus vaccine.
Keywords: epigraph; influenza B virus; vaccine; victoria lineage; yamagata lineage.